ConvaTec Group PLC Director/PDMR Shareholding (4287P)
18 Ottobre 2021 - 05:30PM
UK Regulatory
TIDMCTEC
RNS Number : 4287P
ConvaTec Group PLC
18 October 2021
18 October 2021
ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding
The Company has been notified of the following transactions by
Persons Discharging Managerial Responsibility ("PDMR") in ordinary
shares of 10 pence each in the share capital of the Company
("Shares").
On 14 October 2021, Frank Schulkes, Chief Financial Officer and
a PDMR, received 25 Shares at GBP2.024 per share under the terms of
the Dividend Reinvestment Plan, operated by the Company's
registrars for employees holding shares within its Share Plan
Account. Mr Schulkes' resulting shareholding is 169,180 Shares.
Further, on the same day, Rick Anderson, Non-Executive Director
and a PDMR, received 433 Shares at GBP2.2608 per share under the
Scrip Dividend Scheme. Mr Anderson's resulting shareholding is
210,706 Shares.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Frank Schulkes
2 Reason for the notification
a) Position/Status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name ConvaTec Group Plc
b) LEI 213800LS272L4FIDOH92
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the financial Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")
instrument, type of instrument GB00BD3VFW73
Identification code
b) Nature of the transaction Receipt of Shares under the terms of the Dividend
Reinvestment Plan operated by the Company's registrars for
employees holding shares within
its Share Plan Account.
c) Price(s) and volume(s) Price(s) Volume(s)
GBP2.024 25
d) Aggregated information
- Aggregated volume N/A
- Price N/A
e) Date of the transaction 14 October 2021
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Rick Anderson
2 Reason for the notification
a) Position/Status Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name ConvaTec Group Plc
b) LEI 213800LS272L4FIDOH92
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the financial Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")
instrument, type of instrument GB00BD3VFW73
Identification code
b) Nature of the transaction Receipt of Shares under Scrip Dividend Scheme
c) Price(s) and volume(s) Price(s) Volume(s)
GBP2.2608 433
d) Aggregated information
- Aggregated volume N/A
- Price N/A
e) Date of the transaction 14 October 2021
f) Place of the transaction Outside a trading venue
Enquiries
Analysts and Investors
Kate Postans, VP Investor Relations, ConvaTec +44 (0)782 644 7807
ir@convatec.com
Media
Buchanan: Charles Ryland / Chris Lane +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion care. Our vision, which
encompasses our purpose, is: Pioneering trusted medical solutions
to improve the lives we touch. Our products provide a range of
clinical and economic benefits including infection prevention,
protection of at-risk skin, improved patient outcomes and reduced
total cost of care. To learn more about ConvaTec, please visit
www.convatecgroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFSSITLTLIL
(END) Dow Jones Newswires
October 18, 2021 11:30 ET (15:30 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2023 a Mar 2024